Brief: SOL unit sells rights to ceaCAM1 antibodies
17/07/2015 10:04
July 17(Reuters) - SOL SpA SOLS.MI :
* Said on Thursday that its unit, DIATHEVA Srl, transferred
all rights to antibodies targetting antigen ceaCAM1 to an
American company
* Preclinical studies demonstrate that ceaCAM1 is present at
elevated levels in melanoma and cancer of the bladder, lungs,
colon, pancreas, and stomach
* The license transfers exclusive worldwide rights to
development and commercialization of antibodies ceaCAM1
* In case the product gets the FDA and EMA approval,
DIATHEVA may receive up to USD 44 million, regardless of the
commercialization of the product
* DIATHEVA to receive USD 1.3 million as upfront payment and
reimbursement for R&D and early development milestone expenses
* Agreement envisages additional royalties in case one or
more antibodies derived from the DIATHEVA license will be
commercialized
Source text for Eikon: ID:nBIA1632f
Further company coverage: SOLS.MI
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))